


ISSN: 2249-7137 Vol. 11, Issue 5, May 2021 Impact Factor: SJIF 2021 = 7.492



## **ACADEMICIA**

An International Multidisciplinary Research Journal

(Double Blind Refereed & Peer Reviewed Journal)



DOI: 10.5958/2249-7137.2021.01449.X

## OBSERVATION OF IMMUNOLOGICAL CHANGES DURING CLINICAL CYCLES OF SKIN LEISHMANIOSIS

Makhmudov Farxod Axmedovich\*; Sharopova Gulnoza Samadovna\*\*; Sultonov Sohib Obidovich\*\*\*

\*Assistant, Bukhara State Medical Institute, Bukhara, UZBEKISTAN

\*\*Assistant,
Bukhara State Medical Institute,
Bukhara, UZBEKISTAN

\*\*\*Master Degree Student, Bukhara State Medical Institute, Bukhara, UZBEKISTAN

## **ABSTRACT**

In this article, statistics were obtained from patients with cutaneous leishmaniasis, with particular emphasis on the specific course of clinical cycles and immunological changes. Immunological changes showed a decrease in lymphocytes, a significant increase in IgA, IgM, IgG and CIC. These indicators help patients choose the right treatment. The papillae were covered with a whitish coating, and when pressed, a serous-purulent fluid was released. In patients with a disease duration of more than 2 months, the ulcers, almost completely cleared of necrotic masses, were covered with islands of granulations like pomegranate seeds. To assess the state of cytokine indices in patients with cutaneous leishmaniasis, we studied the indices of the anti-inflammatory cytokine IL-4 and the pro-inflammatory cytokine IL-8 and TNF- $\alpha$ , as well as gamma-interferons. In some patients, the infiltrate was quite pronounced, rising above the ulcer in the form of a roller, which, as it moved away from the ulcer, gradually became flat, aligning with the skin. In patients with relatively fresh ulcers, the bottom was covered with necrotic masses.

**KEYWORDS:** Leishmaniasis, IgM, IgG, Lymphadenitis, parasites, viscerotropic.



ISSN: 2249-7137 Vol. 11, Issue 5, May 2021 Impact Factor: SJIF 2021 = 7.492

## **LITERATURE**

- **1.** Mc Gwire B.S.Satoskar A.R. Leishmaniasis: clinical syndromes and treatment. QJM. 2014; 107: 7-14
- **2.** Reithinger R. Dujardin J.C. Louzir H. Pirmez C. Alexander B. Brooker S. Cutaneous Leishmaniasis. Lancet Infect Dis. 2007; 7: 581-596
- **3.** Anwar M, Hussian MA, Ur-Rehman H. Epidemic of cutaneous leishmaniasis: 109 cases in population of 500. East Mediterr Health J. 2007;13:1211-5.
- **4.** Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420:502-7.
- **5.** AlvarJ.VelezI.D.Bern C.et al.Leishmaniasis world-wide and global estimates of its incidence.PLoS One. 2012; 7: 35671;
- **6.** JaraM.AdauiV.Valencia B.M.et al.Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.JClinMicrobiol. 2013; 51: 1826-1833
- 7. Alvar J. Velez I.D. Bern C. et al. Leishmaniasis world-wide and global estimates of its incidence. PLoS One. 2012; 7: 35671;
- **8.** JaraM.AdauiV.Valencia B.M.et al.Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.JClinMicrobiol. 2013; 51: 1826-1833
- **9.** Antonelli L.R, Dutra W.O, Oliveira R.R. Disparate immunoregulator potentials for double-negative (CD4- CD8-) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis. Infect Immun. 2006;74:6317-23.
- **10.** Олисова О.Ю, Кочергин Н.Г, Исаева М.С, Саидинова Т.О. Эпидемиологические аспекты кожного лейшманиоза в Республике Таджикистан (2009-2014 гг.).
- 11. Российский журнал кожных и венерических болезней. 2017;20(2):111-2.
- **12.** Makhmudov F.A /Changes in skin leyshmaniasis after local treatment/ ACADEMICIA: An International Multidisciplinary Research Journal/ Vol. 11, Issue 1, January 2021/ p. 1745-1750
- **13.** Geiger B, Wenzel J, Hantschke M, Haase I, Stander S, von Stebut E. Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. Br J Dermatol. 2010;162:870-4.
- **14.** Исаева МС, Саидинова ТО. Современные аспекты кожного лейшманиоза. Вестник Авиценны. 2016;1:116-22
- **15.** Farxod A. Makhmudov, Gulnoza S. Sharopova/ Intravenous laser blood irradiation in the complex treatment of patients with cutaneous leishmaniasis / Journal of Natural Remedies Vol. 22, No. 1(1), (2021) p-108-111.